Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells

Basic Research in Cardiology, Supplement

Volumn 93, Issue 3, 1998, Pages 54-57

  Weber, A A ^a   Zucker, T P ^a   Hasse, A ^a   Bonisch D ^a   Wittpoth, M ^a   Schror K ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cyclooxygenase 2; Iloprost; PGI1; PGI2; Proliferation; Prostacyclin receptors; Smooth muscle cells

Indexed keywords

CYCLOOXYGENASE 2; ILOPROST; PLATELET DERIVED GROWTH FACTOR BB; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; DRUG TOLERANCE; MITOGENESIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL DIVISION; CORONARY VESSELS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PROSTAGLANDINS; VASODILATION;

EID: 0032433111     PISSN: 01759418     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Allan G, Follenfant MJ, Lidbury P, Oliver PL, Whittle BJ (1985) The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey. Br J Pharmacol 85: 547-55
2. Bauters C, Meurice T, Hamon M, McFadden E, Lablanche JM, Bertrand ME (1996) Mechanisms and prevention of restenosis: From experimental models to clinical practice. Cardiovasc Res 31: 835-846
3. Darius N, Nixdorff U, Zander J, Rupprecht HJ, Erbel R, Meyer J (1992) Effects of ciprostene on restenosis rate during therapeutical transluminal coronary angioplasty. Agents Actions 37: 305-311
4. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: Results of a randomised placebo controlled trial. Br Heart J 71: 7-15
5. 2 induces cell signalling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol 319: 327-332
6. Huttner JJ, Gwebu ET, Panganamela RV, Milo GE, Cornwell DG (1977) Fatty acids and their prostaglandin derivatives: Inhibitors of proliferation in aortic smooth muscle cells. Science 197: 289-291
7. Isaka Y, Handa N, Imaizumi M, Kimura K, Kamada T (1991) Effect of TRK-100, a stable orally active prostacyclin analogue, on platelet function and platelet size in atherothrombotic strokes. Thromb Haemost 65: 344-350
8. Jaschonek K, Faul C, Schmidt H, Renn W (1988) Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol 147: 187-196
9. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL (1995) Identification and characterization of a prostaglandin transporter. Science 268: 866-869
10. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ (1990) Effects of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 15: 691-697
11. 1. Exp Cell Res 160: 117-125
12. Otto JC, Smith WL (1995) Prostaglandin endoperoxide synthases-1 and -2. J Lipid Med 12: 139-156
13. Pomerantz KB, Hajjar (1989) Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis 9: 413-429
14. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB (1994) Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 14: 1021-1031
15. Schröder H, Schrör K (1993) Prostacyclin-dependent cyclic AMP formation in endothelial cells. Naunyn-Schmiedeberg's Arch Pharmacol 347: 101-104
16. 2) and atherosclerosis. In: Rubanyi G, Dzau V (eds) Endothelium in Clinical Practice: Source and Target of Novel Concepts and Therapies. Marcel Dekker, Richmond, pp 1-44
17. 1, prostacyclin and ZK 36.374 stimulation. In: Schrör K (ed) Prostaglandins and Other Eicosanoids in the Cardiovascular System. Karger, Basel, pp 273-278
18. Weissberg P, Clesham GJ, Bennet MR (1996) Is vascular smooth muscle cell proliferation beneficial? Lancet 347: 305-307
19. Wu KK (1995) Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 33: 179-207
20. 2 and involves upregulation of thromboxane receptor mRNA. Circulation 97: 589-595